NCT05125757|Unknown
Lifestyle Modification in Psoriatic Patients With Fatty Liver
Response of Fatty Liver to Lifestyle Modification in Psoriasis Patients
Loading search results
Response of Fatty Liver to Lifestyle Modification in Psoriasis Patients
Sponsor study identifier
interventional
60
1 country
1
Study Start
September 13, 2021
Actual (reported)Primary Completion
March 15, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 15, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Several recent reports have shown an increased prevalence of nonalcoholic fatty liver disease (NAFLD) in those with psoriasis, which may reflect the increased occurrence of metabolic syndrome in this patient population.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 15, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 13, 2021
Actual (reported)October 17, 2021
Actual (reported)November 18, 2021
Actual (reported)March 15, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
March 15, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Psoriasis Area and Severity Index
it is an index used to measure level and severity of psoriasis
It will be measured after 12 weeks
Dermatology Life Quality Index
It will be measured after 12 weeks
triglycerides
It will be measured after 12 weeks
AST
It will be measured after 12 weeks
ALT
It will be measured after 12 weeks
BMI
It will be measured after 12 weeks
The patients of this group will receive their usual immuno-modulating therapy plus life style modification (energy or diet restriction in addition to daily walking, 15000 steps)
The participants of this group will receive their usual immuno-modulating therapy and continuing their usual diet and activities
for 12 week, the patients of this group will receive their usual immuno-modulating therapy plus life style modification (energy or diet restriction in addition to daily walking, 15000 steps)
the patients will receive the usual immuno-modulating therapy with continued usual diet and activities
Faculty of Physical Therapy Cairo University
Giza, Dokki, Egypt
Ali Ismail, lecturer
Cairo University
First Submitted
October 17, 2021
First Posted
November 18, 2021
Study Start
September 13, 2021
Actual (reported)Primary Completion
Resolvin D1 in Psoriasis Before and After Narrowband UVB Phototherapy
Omega 3 Supplementation in Children With Non Alcoholic Fatty Liver
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
March 15, 2022
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 15, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
November 18, 2021
Record last verified: 2021-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: